Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The zoonotic emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and the ensuing coronavirus disease 2019 (COVID-19) pandemic have profoundly affected …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …

A sensitive biological system and a detector system with appropriate transducers for
obtaining the output signals make up a biosensor. These devices have a wide range of …

The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants
in different continents is causing a major concern in human global health. These variants …

Novel coronavirus (COVID-19 or 2019-nCoV or SARS-CoV-2), which suddenly emerged in
December 2019 is still haunting the entire human race and has affected not only the …

Coronaviruses (CoVs) stand out for their large RNA genome and complex RNA-synthesizing
machinery comprising 16 nonstructural proteins (nsps). The bifunctional nsp14 contains 3 …

Clinically approved antiviral drugs are currently available for only 10 of the more than 220
viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need …